Hypertensive emergencies in pregnancies in underresourced countries

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 2, 2008, Pages 91-95

  Moodley, Jack ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDRALAZINE; DOPAMINE; LABETALOL; METHYLDOPA; NIFEDIPINE;

CAUSE OF DEATH; CESAREAN SECTION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; ECLAMPSIA; EMERGENCY; FETUS HEART RATE; FLUID BALANCE; HUMAN; HYPOTENSION; MATERNAL HYPERTENSION; NEWBORN DISEASE; PATIENT REFERRAL; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SOLUTIO PLACENTAE; SYMPTOMATOLOGY;

ANTIHYPERTENSIVE AGENTS; ECLAMPSIA; EMERGENCY TREATMENT; FEMALE; HEALTH RESOURCES; HUMANS; HYPERTENSION; MAGNESIUM SULFATE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41849100742     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000313299.51478.4d     Document Type: Review

References (26)

1. Saving Mothers. The Report of the National Confidential Enquiries into Maternal Deaths in South Africa 2002-2004. Pretoria: Department of Health; 2006. This is a triennial report of maternal deaths in South Africa. This is the only underresourced country to have a formal confidential enquiry into maternal deaths at a national level.
2. Lindheimer MD, Romero R. Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension 2007; 50:1-2.
3. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFIt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
4. Levine RJ, Lan C, Quan C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:922-1005. This review covers the important issues associated with antiangiogenic factors and preeclampsia.
5. Rana S, Karumanchi A, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50:1-6.
6. Knight M, on behalf of UKOSS. Eclampsia in the United Kingdom 2005. Br J Obstet Gynaecol 2007; 114:1072-1078.
7. Douglas KA, Redman CW. Eclampsia in the United Kingdom. Br Med J 1994; 309:1066-1074.
8. Tuffnell DJD, Jankowitz SW, Lindow G, et al. Outcomes of preeclampsia, eclampsia in Yorkshire 1999/2003. Br J Obstet Gynaecol 2005; 11297:875-880.
9. Menzies J, Magee LA, Li J, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstet Gynecol 2007; 110:121-127.
10. McCaw-Binns AM, Ashley DE, Knight LP, et al. Strategies to prevent eclampsia in a developing country: 1. Re-organisation of maternity services. Int J Gynecol Obstet 2004; 87:287-294.
11. The Magpie Trial Collaborative Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877-1890.
12. Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulphate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2006; 108:833-838.
13. Why Mothers Die 2000-2002. Confidential enquiries into maternal deaths in the United Kingdom. London: RCOG; 2004.
14. Von Dadelszen P, Menzies J, Gilgoff S, et al. Evidence-based management for preeclampsia. Front Biosc 2007; 12:2876-2889. This is a good overview of the management of preeclampsia.
15. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. Br Med J 1999; 381:1332-1336.
16. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for the treatment of severe hypertension in pregnancy: a meta analysis. Br Med J 2003; 327: 955-960.
17. Vigil-De Gracia P, Ruiz E, Lopez JC, et al. Management of severe hypertension in the postpartum period with intravenous dihydralzine or labetalol: a randomized clinical trial. Hyperten Pregnancy 2007; 26:163-171.
18. Vigil-De Gracia P, Lasso M, Ruiz E, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006; 128:157-162.
19. Ganzevoort W, Rep A, Bonsel GJ, et al. Dynamics and incidence patterns of maternal complications in early onset hypertension of pregnancy. Br J Obstet Gynaecol 2007; 114:741-750.
20. Morgan P. The effect of increasing central blood volume to decrease the incidence of hypotension following spinal anaesthesia for caesarean section. In: Halpern SH, Douglas MJ, editors. Evidence-based obstetric anaesthesia. London: BMJ Books; 2005.
21. Steyn DW, Steyn P. Low dose dopamine for women with severe preeclampsia. Cochrane Database Syst Rev 2007; (1):CD003515.
22. Keiseb J, Moodley J, Connelly CA. Comparison of the efficacy of continuous furosemide and low dose dopamine infusion in preeclampsia/eclampsia related oliguria in the immediate postpartum period. Hypertension in Pregnancy 2002; 21:225-234.
23. Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956-966. This is an excellent overview of the differential diagnosis of severe preeclampsia. It is of clinical importance.
24. Khan KS, Wojdyla D, Say L, et al. WHO Analysis of causes of maternal deaths: a systematic review. Lancet 2006; 367:1066-1074.
25. Abdel-Hady el-S, Mashaly AM, Sherief LS, et al. Why mothers die in Dakahlia, Egypt? J Obstet Gynaecol Res 2007; 33:283-287.
26. Oyieke JB, Obore S, Kigondu CS. Millennium development goal 5: a review of maternal mortality at the Kenyatta National Hospital, Nairobi. E Afr Med J 2006; 83:4-9.